Viemed Healthcare Inc (VMD)

$8.72

-0.05

(-0.57%)▲

Market is closed - opens 7 PM, 15 Oct 2024

Performance

  • $8.68
    $8.96
    $8.72
    downward going graph

    0.5%

    Downside

    Day's Volatility :3.19%

    Upside

    2.71%

    downward going graph
  • $5.90
    $10.44
    $8.72
    downward going graph

    32.34%

    Downside

    52 Weeks Volatility :43.49%

    Upside

    16.48%

    downward going graph

Returns

PeriodViemed Healthcare IncSector (Health Care)Index (Russel 2000)
3 Months
27.67%
4.7%
0.0%
6 Months
7.74%
11.6%
0.0%
1 Year
33.54%
18.9%
0.0%
3 Years
51.99%
20.9%
-21.9%

Highlights

Market Capitalization
340.5M
Book Value
$3.08
Earnings Per Share (EPS)
0.23
PE Ratio
37.91
Wall Street Target Price
12.27
Profit Margin
4.6%
Operating Margin TTM
7.63%
Return On Assets TTM
6.79%
Return On Equity TTM
8.4%
Revenue TTM
205.7M
Revenue Per Share TTM
5.34
Quarterly Revenue Growth YOY
26.900000000000002%
Gross Profit TTM
84.7M
EBITDA
41.5M
Diluted Eps TTM
0.23
Quarterly Earnings Growth YOY
-0.37
EPS Estimate Current Year
0.24
EPS Estimate Next Year
0.36
EPS Estimate Current Quarter
0.07
EPS Estimate Next Quarter
0.08

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Viemed Healthcare Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 40.71%

Current $8.72
Target $12.27

Company Financials

FY18Y/Y Change
Revenue
65.3M
↑ 39.09%
Net Income
10.2M
↑ 24.47%
Net Profit Margin
15.59%
↓ 1.83%
FY19Y/Y Change
Revenue
80.3M
↑ 22.96%
Net Income
8.5M
↓ 16.23%
Net Profit Margin
10.62%
↓ 4.97%
FY20Y/Y Change
Revenue
131.3M
↑ 63.61%
Net Income
31.5M
↑ 269.85%
Net Profit Margin
24.01%
↑ 13.39%
FY21Y/Y Change
Revenue
117.1M
↓ 10.85%
Net Income
9.1M
↓ 71.06%
Net Profit Margin
7.8%
↓ 16.21%
FY22Y/Y Change
Revenue
138.8M
↑ 18.6%
Net Income
6.2M
↓ 31.82%
Net Profit Margin
4.48%
↓ 3.32%
FY23Y/Y Change
Revenue
186.4M
↑ 34.24%
Net Income
10.2M
↑ 64.63%
Net Profit Margin
5.5%
↑ 1.02%
Q1 FY23Q/Q Change
Revenue
39.6M
↑ 5.46%
Net Income
1.5M
↓ 37.78%
Net Profit Margin
3.84%
↓ 2.66%
Q2 FY23Q/Q Change
Revenue
43.3M
↑ 9.49%
Net Income
2.3M
↑ 53.59%
Net Profit Margin
5.38%
↑ 1.54%
Q3 FY23Q/Q Change
Revenue
49.4M
↑ 14.06%
Net Income
2.9M
↑ 25.28%
Net Profit Margin
5.91%
↑ 0.53%
Q4 FY23Q/Q Change
Revenue
52.1M
↑ 5.55%
Net Income
3.5M
↑ 19.12%
Net Profit Margin
6.67%
↑ 0.76%
Q1 FY24Q/Q Change
Revenue
50.6M
↓ 2.97%
Net Income
1.6M
↓ 53.9%
Net Profit Margin
3.17%
↓ 3.5%
Q2 FY24Q/Q Change
Revenue
55.0M
↑ 8.64%
Net Income
1.5M
↓ 8.42%
Net Profit Margin
2.67%
↓ 0.5%
FY18Y/Y Change
Total Assets
53.5M
↑ 42.01%
Total Liabilities
18.5M
↑ 32.59%
FY19Y/Y Change
Total Assets
82.6M
↑ 54.31%
Total Liabilities
38.9M
↑ 110.35%
FY20Y/Y Change
Total Assets
112.6M
↑ 36.28%
Total Liabilities
30.9M
↓ 20.64%
FY21Y/Y Change
Total Assets
118.0M
↑ 4.8%
Total Liabilities
23.1M
↓ 25.03%
FY22Y/Y Change
Total Assets
117.0M
↓ 0.78%
Total Liabilities
19.9M
↓ 13.8%
FY23Y/Y Change
Total Assets
154.1M
↑ 31.66%
Total Liabilities
40.8M
↑ 104.47%
Q1 FY23Q/Q Change
Total Assets
124.6M
↑ 6.49%
Total Liabilities
24.6M
↑ 23.28%
Q2 FY23Q/Q Change
Total Assets
149.1M
↑ 19.64%
Total Liabilities
44.6M
↑ 81.4%
Q3 FY23Q/Q Change
Total Assets
149.4M
↑ 0.19%
Total Liabilities
40.6M
↓ 9.02%
Q4 FY23Q/Q Change
Total Assets
154.1M
↑ 3.15%
Total Liabilities
40.8M
↑ 0.5%
Q1 FY24Q/Q Change
Total Assets
154.9M
↑ 0.5%
Total Liabilities
38.6M
↓ 5.36%
Q2 FY24Q/Q Change
Total Assets
163.9M
↑ 5.86%
Total Liabilities
42.8M
↑ 10.79%
FY18Y/Y Change
Operating Cash Flow
22.4M
↑ 86.03%
Investing Cash Flow
-5.3M
↑ 48.36%
Financing Cash Flow
-11.8M
↑ 52.78%
FY19Y/Y Change
Operating Cash Flow
19.1M
↓ 14.67%
Investing Cash Flow
-12.8M
↑ 141.67%
Financing Cash Flow
-3.3M
↓ 71.63%
FY20Y/Y Change
Operating Cash Flow
35.1M
↑ 83.95%
Investing Cash Flow
-8.4M
↓ 34.31%
Financing Cash Flow
-9.1M
↑ 172.02%
FY21Y/Y Change
Operating Cash Flow
22.5M
↓ 35.93%
Investing Cash Flow
-19.7M
↑ 134.65%
Financing Cash Flow
-5.3M
↓ 41.33%
FY22Y/Y Change
Operating Cash Flow
27.7M
↑ 23.36%
Investing Cash Flow
-24.0M
↑ 21.42%
Financing Cash Flow
-15.3M
↑ 186.9%
Q1 FY23Q/Q Change
Operating Cash Flow
10.5M
↑ 36.6%
Investing Cash Flow
-3.9M
↓ 47.07%
Financing Cash Flow
39.0K
↓ 100.8%
Q2 FY23Q/Q Change
Operating Cash Flow
7.6M
↓ 27.37%
Investing Cash Flow
-32.2M
↑ 724.76%
Financing Cash Flow
11.3M
↑ 28782.05%

Technicals Summary

Sell

Neutral

Buy

Viemed Healthcare Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Viemed Healthcare Inc
Viemed Healthcare Inc
17.36%
7.74%
33.54%
51.99%
10.1%
Stryker Corporation
Stryker Corporation
-3.29%
6.07%
36.21%
35.07%
67.35%
Boston Scientific Corp.
Boston Scientific Corp.
4.84%
29.15%
74.75%
100.69%
127.64%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
0.39%
-21.94%
-2.3%
-37.92%
-8.63%
Abbott Laboratories
Abbott Laboratories
-0.32%
7.68%
27.2%
-0.2%
43.02%
Medtronic Plc
Medtronic Plc
-0.11%
12.19%
25.45%
-29.54%
-16.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Viemed Healthcare Inc
Viemed Healthcare Inc
37.91
37.91
NA
0.24
0.08
0.07
NA
3.08
Stryker Corporation
Stryker Corporation
39.7
39.7
2.61
12.01
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
71.18
71.18
2.14
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.41
27.41
3.63
2.6
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
36.99
36.99
4.25
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.1
30.1
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Viemed Healthcare Inc
Viemed Healthcare Inc
Buy
$340.5M
10.1%
37.91
4.6%
Stryker Corporation
Stryker Corporation
Buy
$137.1B
67.35%
39.7
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$128.9B
127.64%
71.18
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.9B
-8.63%
27.41
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$204.0B
43.02%
36.99
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.4B
-16.8%
30.1
12.06%

Insights on Viemed Healthcare Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 50.59M → 54.96M (in $), with an average increase of 8.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 3.47M → 1.46M (in $), with an average decrease of 31.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 76.8% return, outperforming this stock by 39.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 101.7% return, outperforming this stock by 50.6%

Institutional Holdings

  • Thrivent Financial For Lutherans

    8.77%

  • BlackRock Inc

    7.50%

  • Nantahala Capital Management, LLC

    7.39%

  • Vanguard Group Inc

    4.59%

  • Forager Capital Management, LLC

    4.42%

  • Wasatch Advisors LP

    3.98%

Company Information

viemed is a respiratory disease management company. our mission is to educate, nurture, and inspire our patients to lead better lives. we accomplish this through a highly effective home treatment model that integrates easily into the processes of our referral partners to effectively transition patients from the hospital to their home or other long-term care setting. while our respiratory care practitioners, trained as copd educators, deliver therapy and counseling to patients in their home utilizing the most effective technology available, our care consultants work with hospitals, aco’s, snf’s and other referral sources to simplify the administrative process of transitioning patients from hospital to home care. we achieve industry leading outcomes in hospital readmissions and patient satisfaction which has resulted in us becoming one of the largest home non-invasive ventilation providers in the usa.

Organization
Viemed Healthcare Inc
Employees
1121
CEO
Mr. Casey Hoyt
Industry
Health Services

Discover More

FAQs